Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 The most common treatment-emergent adverse events during the maintenance phase (≥5.0%)

From: A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

TEAE, n (%) Pemetrexed/BSC (n = 28) BSC (n = 27)
  All Grades Grade 3/4 All Grades Grade 3/4
Dyspnea 2 (7.1) 0 (0.0) 4 (14.8) 1 (3.7)
Anemia 3 (10.7) 2 (7.1)a 1 (3.7) 1 (3.7)b
Chest/thorax pain 3 (10.7) 0 (0.0) 3 (11.1) 0 (0.0)
Neutropenia 2 (7.1) 2 (7.1)b 0 (0.0) 0 (0.0)
Abnormal ALT 2 (7.1) 0 (0.0) 1 (3.7) 1 (3.7)
Fatigue 1 (3.6) 0 (0.0) 2 (7.4) 1 (3.7)
Nausea 2 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
Vomiting 2 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
  1. Abbreviations: ALT = alanine aminotransferase; BSC = best supportive care; TEAE = treatment-emergent adverse event.
  2. a1 (3.6%) patient experienced grade 3 or 4 anemia that was considered by the investigator to be possibly study drug-related.
  3. bConsidered to be possibly drug-related.